Gender-specific differences in patients with psoriatic arthritis receiving ustekinumab or tumour necrosis factor inhibitor: real-world data.
| Autor: | Kuijk, Arno W R Van, Nurmohamed, Mike T, Siebert, Stefan, Bergmans, Paul, Vlam, Kurt de, Gremese, Elisa, Joven-Ibáñez, Beatriz, Korotaeva, T V, Lavie, Frederic, Sharaf, Mohamed, Noël, Wim, Theander, Elke, Smolen, Josef S, Gossec, Laure, Horst-Bruinsma, Irene E van der |
|---|---|
| Předmět: |
THERAPEUTIC use of monoclonal antibodies
PSORIATIC arthritis STATISTICS SCIENTIFIC observation CONFIDENCE intervals HEALTH outcome assessment ANTIRHEUMATIC agents SEX distribution TREATMENT effectiveness TUMOR necrosis factors DESCRIPTIVE statistics SYMPTOMS RESEARCH funding DATA analysis LOGISTIC regression analysis LONGITUDINAL method PROBABILITY theory CHEMICAL inhibitors |
| Zdroj: | Rheumatology; Oct2023, Vol. 62 Issue 10, p3382-3390, 9p |
| Abstrakt: | Objective Investigate effects of gender on disease characteristics and treatment impact in patients with PsA. Methods PsABio is a non-interventional European study in patients with PsA starting a biological DMARD [bDMARD; ustekinumab or TNF inhibitor (TNFi)]. This post-hoc analysis compared persistence, disease activity, patient-reported outcomes and safety between male and female patients at baseline and 6 and 12 months of treatment. Results At baseline, disease duration was 6.7 and 6.9 years for 512 females and 417 males respectively. Mean (95% CI) scores for females vs males were: clinical Disease Activity Index for Psoriatic Arthritis (cDAPSA), 32.3 (30.3, 34.2) vs 26.8 (24.8, 28.9); HAQ-Disability Index (HAQ-DI), 1.3 (1.2, 1.4) vs 0.93 (0.86, 0.99); total PsA Impact of Disease-12 (PsAID-12) score, 6.0 (5.8, 6.2) vs 5.1 (4.9, 5.3), respectively. Improvements in scores were smaller in female than male patients. At 12 months, 175/303 (57.8%) female and 212/264 (80.3%) male patients achieved cDAPSA low disease activity, 96/285 (33.7%) and 137/247 (55.5%), achieved minimal disease activity (MDA), respectively. HAQ-DI scores were 0.85 (0.77, 0.92) vs 0.50 (0.43, 0.56), PsAID-12 scores 3.5 (3.3, 3.8) vs 2.4 (2.2, 2.6), respectively. Treatment persistence was lower in females than males (P ≤ 0.001). Lack of effectiveness was the predominant reason to stop, irrespective of gender and bDMARD. Conclusions Before starting bDMARDs, females had more severe disease than males and a lower percentage reached favourable disease states, with lower persistence of treatment after 12 months. A better understanding of the mechanisms underlying these differences may improve therapeutic management in females with PsA. Trial registration ClinicalTrials.gov, https://clinicaltrials.gov , NCT02627768 [ABSTRACT FROM AUTHOR] |
| Databáze: | Complementary Index |
| Externí odkaz: |
|